Erythropoietin (EPO) is a potential therapeutic for Alzheimer’s disease (AD), but has limited brain penetration, requiring high systemic doses that lead to hematopoietic side effects. Here, EPO is linked to early-onset autosomal dominant Alzheimer disease.